Text Size

Exercise, Oxidative Stress and HIV

This study has been completed.
Sponsor:
Information provided by:
Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov Identifier:
NCT00950937
First received: February 16, 2009
Last updated: August 4, 2009
Last verified: August 2009
History of Changes
Results First Received: February 16, 2009  
Study Type: Observational
Study Design: Observational Model: Case Control;   Time Perspective: Prospective
Condition: HIV Infections

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
HIV Group HIV infected persons
Control Group Non HIV-infected persons

Participant Flow:   Overall Study
    HIV Group     Control Group  
STARTED     14     14  
COMPLETED     14     14  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
HIV Group HIV infected persons
Control Group Non HIV-infected persons
Total Total of all reporting groups

Baseline Measures
    HIV Group     Control Group     Total  
Number of Participants  
[units: participants]
 		  14     14     28  
Age  
[units: participants]
 		     
<=18 years     0     0     0  
Between 18 and 65 years     14     14     28  
>=65 years     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation 		  39.2  ± 8.7     36  ± 10.6     37.5  ± 9.5  
Gender  
[units: participants]
 		     
Female     7     7     14  
Male     7     7     14  
Region of Enrollment  
[units: participants]
 		     
Brazil     14     14     28  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Total Glutathione   [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ]
  Show Outcome Measure 1

2.  Secondary:   Catalase Activity   [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ]
  Show Outcome Measure 2

3.  Secondary:   Glutathione S-transferase (GST)   [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ]
  Show Outcome Measure 3

4.  Secondary:   Lipid Peroxidation   [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ]
  Show Outcome Measure 4

5.  Secondary:   T CD4   [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ]
  Show Outcome Measure 5

6.  Secondary:   Neutrophil Count   [ Time Frame: 3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise). ]
  Show Outcome Measure 6

7.  Secondary:   Peak Oxygen Uptake   [ Time Frame: 1 time, before the exercise protocol ]
  Show Outcome Measure 7


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Pedro Dall'Ago
Organization: Hospital de Clínicas de Porto Alegre
phone: 555133038751
e-mail: pdallago@pq.cnpq.br


No publications provided


Responsible Party: Pedro Dall'Ago, Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov Identifier: NCT00950937     History of Changes
Other Study ID Numbers: 06067
Study First Received: February 16, 2009
Results First Received: February 16, 2009
Last Updated: August 4, 2009
Health Authority: Brazil: National Committee of Ethics in Research